Guess Who Picked Health Insurance Innovations Inc. (NASDAQ:HIIQ) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Health Insurance Innovations Inc. (NASDAQ:HIIQ) reported that Kosloske Michael W. has picked up 3,841,767 of common stock as of 2017-03-17.
The acquisition brings the aggregate amount owned by Kosloske Michael W. to a total of 3,841,767 representing a 24.38% stake in the company.
For those not familiar with the company, Health Insurance Innovations, Inc. is a developer, distributor and virtual administrator of individual and family health insurance plans and supplemental products. The Company sells individual and family insurance plans (IFP) that include short-term medical (STM) insurance plans and hospital indemnity plans. The Company operates through Insurance Plan Development and Distribution (IPD) segment. Its STM plans cover individuals for over 360 days with a range of co-pay and deductible options. Its individual major medical (IMM) plans cover prescription drugs, pre-existing conditions and preventive care, while STM plans provide optional coverage for prescription drugs. The Company’s hospital indemnity plans provide a daily cash benefit for hospital treatment and doctor office visits, as well as accidental injury and death or dismemberment benefits. It provides supplemental insurance products, including pharmacy benefit cards, dental plans, vision plans and cancer/critical illness plans.
A glance at Health Insurance Innovations Inc. (NASDAQ:HIIQ)’s key stats reveals a current market capitalization of 257.67 Million based on 8.04 Million shares outstanding and a price at last close of $16.58 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-09, Murley picked up 9,000 at a purchase price of $16.09. This brings their total holding to 25,700 as of the date of the filing.
On the sell side, the most recent transaction saw Wang unload 3,002 shares at a sale price of $16.95. This brings their total holding to 246,001.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Health Insurance Innovations Inc. (NASDAQ:HIIQ) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Celgene Corp /de/ Picked Up Alliqua Biomedical Inc. (NASDAQ:ALQA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Alliqua Biomedical Inc. (NASDAQ:ALQA) reported that Celgene Corp /de/ has picked up 8,025,194 of common stock as of 2017-03-16.
The acquisition brings the aggregate amount owned by Celgene Corp /de/ to a total of 8,025,194 representing a 19.9% stake in the company.
For those not familiar with the company, Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers TheraBond 3D Antimicrobial Barrier Systems and SilverSeal.
A glance at Alliqua Biomedical Inc. (NASDAQ:ALQA)’s key stats reveals a current market capitalization of 17.77 Million based on 35.11 Million shares outstanding and a price at last close of $0.599 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-02-27, Celgene picked up 4,000,000 at a purchase price of $0.50. This brings their total holding to 7,046,100 as of the date of the filing.
On the sell side, the most recent transaction saw Kalen unload 24,057,980 shares at a sale price of $0.04. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Alliqua Biomedical Inc. (NASDAQ:ALQA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Valeant Pharmaceuticals International Inc. (NYSE:VRX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Valeant Pharmaceuticals International Inc. (NYSE:VRX) reported that Va Partners I, Llc. has picked up 16,937,431 of common stock as of 2017-03-16.
The acquisition brings the aggregate amount owned by Va Partners I, Llc. to a total of 16,937,431 representing a 4.9% stake in the company.
For those not familiar with the company, Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.
A glance at Valeant Pharmaceuticals International Inc. (NYSE:VRX)’s key stats reveals a current market capitalization of 3.87 Billion based on 341.19 Million shares outstanding and a price at last close of $11.20 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-15, De picked up 10,000 at a purchase price of $10.80. This brings their total holding to 25,190 as of the date of the filing.
On the sell side, the most recent transaction saw Pershing unload 18,114,432 shares at a sale price of $11.00. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Valeant Pharmaceuticals International Inc. (NYSE:VRX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Rti Surgical Inc. (NASDAQ:RTIX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Rti Surgical Inc. (NASDAQ:RTIX) reported that Krensavage Asset Management, Llc. has picked up 3,561,351 of common stock as of 2017-03-16.
The acquisition brings the aggregate amount owned by Krensavage Asset Management, Llc. to a total of 3,561,351 representing a 6.1% stake in the company.
For those not familiar with the company, RTI Surgical, Inc. is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes, and manufactures metal and synthetic implants for distribution to hospitals and surgeons. The Company distributes its implants and services in approximately 50 states and in over 45 countries across the world.
A glance at Rti Surgical Inc. (NASDAQ:RTIX)’s key stats reveals a current market capitalization of 219.23 Million based on 58.46 Million shares outstanding and a price at last close of $3.75 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-02, Singer picked up 10,000 at a purchase price of $3.79. This brings their total holding to 30,270 as of the date of the filing.
On the sell side, the most recent transaction saw Smith unload 15,000 shares at a sale price of $4.31. This brings their total holding to 18,225.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Rti Surgical Inc. (NASDAQ:RTIX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Adage Capital Management is Buying Fluidigm Corp (NASDAQ:FLDM) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Fluidigm Corp (NASDAQ:FLDM) reported that Adage Capital Management has picked up 1,546,209 of common stock as of 2017-03-13.
The acquisition brings the aggregate amount owned by Adage Capital Management to a total of 1,546,209 representing a 5.29% stake in the company.
For those not familiar with the company, Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
A glance at Fluidigm Corp (NASDAQ:FLDM)’s key stats reveals a current market capitalization of 146.92 Million based on 29.21 Million shares outstanding and a price at last close of $4.92 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-02-15, Levin picked up 825 at a purchase price of $6.00. This brings their total holding to 6,344,568 as of the date of the filing.
On the sell side, the most recent transaction saw Worthington unload 6,000 shares at a sale price of $11.50. This brings their total holding to 6,815.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Fluidigm Corp (NASDAQ:FLDM) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Morgan Stanley is Buying Ophthotech Corp. (NASDAQ:OPHT) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ophthotech Corp. (NASDAQ:OPHT) reported that Morgan Stanley has picked up 10,932,054 of common stock as of 2017-03-08.
The acquisition brings the aggregate amount owned by Morgan Stanley to a total of 10,932,054 representing a 6.1% stake in the company.
For those not familiar with the company, Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV). Fovista is being tested in Phase III clinical development. In addition, it has initiated additional clinical trials to evaluate the potential additional benefits of Fovista administered in combination with anti-VEGF drugs in wet AMD patients, known as Fovista Expansion Studies. Zimura has completed a small, multicenter, uncontrolled, open label Phase I/IIa clinical trial.
A glance at Ophthotech Corp. (NASDAQ:OPHT)’s key stats reveals a current market capitalization of 129.27 million based on 35.81 Million shares outstanding and a price at last close of $3.62 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-06-03, Bolte picked up 3,500 at a purchase price of $56.97. This brings their total holding to 6,000 as of the date of the filing.
On the sell side, the most recent transaction saw Bolte unload 6,000 shares at a sale price of $4.83. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ophthotech Corp. (NASDAQ:OPHT) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Cpmg Inc. Picked Up Reata Pharmaceuticals Inc. (NASDAQ:RETA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported that Cpmg Inc. has picked up 3,161,180 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by Cpmg Inc. to a total of 3,161,180 representing a 20.9% stake in the company.
For those not familiar with the company, Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company’s lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich’s ataxia, mitochondrial myopathies and metastatic melanoma.
A glance at Reata Pharmaceuticals Inc. (NASDAQ:RETA)’s key stats reveals a current market capitalization of 659.60 million based on 22.34 Million shares outstanding and a price at last close of $28.14 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-30, Traweek picked up 9,392 at a purchase price of $21.72. This brings their total holding to 1,926,034 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Reata Pharmaceuticals Inc. (NASDAQ:RETA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Up Optimizerx Corp (OTCMKTS:OPRX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Optimizerx Corp (OTCMKTS:OPRX) reported that Wolverine Asset Management Llc. has picked up 2,155,860 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by Wolverine Asset Management Llc. to a total of 2,155,860 representing a 7.3% stake in the company.
For those not familiar with the company, OptimizeRx Corporation is a technology solutions company. The Company focuses on the healthcare industry. The Company connects patients, physicians and pharmaceutical manufacturers through technology. The Company’s solutions provide pharmaceutical manufacturers a direct to physician channel for communicating and promoting products. It provides healthcare providers a means to provide sampling and coupons without having to physically store samples on site. The Company’s principal products and applications include SampleMD, OPTIMIZEHR and OPTIMIZERx.com. SampleMD is a virtual Patient Support Center. OPTIMIZEHR is a consulting practice focused on educating and working with pharmaceutical manufacturers on identifying, formulating and implementing new electronic prescribing (eRx) media strategies for promoting their products. OPTIMIZERx.com is a portal to healthcare savings for patients to centrally review and participate in prescription and healthcare savings and support programs.
A glance at Optimizerx Corp (OTCMKTS:OPRX)’s key stats reveals a current market capitalization of 23.84 million based on 29.67 Million shares outstanding and a price at last close of $0.750 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-13, Pinney picked up 4,000 at a purchase price of $0.80. This brings their total holding to 781,079 as of the date of the filing.
On the sell side, the most recent transaction saw Radoff unload 631,100 shares at a sale price of $1.41. This brings their total holding to 2,289,200.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Optimizerx Corp (OTCMKTS:OPRX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.